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Summary A total of 142 patients With multiple myeloma received VAD as remission induction therapy.
Seventy-five were previously untreated and 67 had relapsed (31) or refractory disease (36). Vincristine (total
dose 1.6 mg) was infused with doxorubicin 36 mg m- by continuous ambulatory pump over 4 days. In
addition. oral dexamethasone 40 mg day-' was given for 4 days. Interrmittent dexamethasone was only given
to 19 patients. Courses were repeated every 21 days. The overall response rate was 84% [27% complete
response (CR)l in previously untreated patients and 61% (3% CR) in patients with relapsed and refractory
disease. The median survival was 36 months for untreated patients and 10 months for those who had received
prior therapy. VAD was well tolerated: however, despite prophylaxis. 54% patients received antibiotics at
some time dunrng therapy and 37% had dyspepsia. Twenty-three patients subsequently received a transplant
(eight allografts. eight marrow autografts and seven peripheral blood stem cell transplants). Eight have died -
four in the allogeneic group and four in the autologous group. The overall median survival of transplanted
patients has not yet been reached. VAD is an effective, out-patient therapy for inducing remission in multiple
myeloma. Post-remission therapy needs to be optimised. but it is likely that the needs of previously untreated
patients may be different from those with relapsed and refractory disease.
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Before the use of chemotherapy for multiple myeloma the
median survival was 7 months from the date of symptomatic
therapy. Melphalan and prednisolone combination therapy
was associated with a 50% response rate and a median
survival of 24 months. (Woodruff. 1981). The addition of
cyclophosphamide in our hands gave a modest improvement
in response rate (57%) and was associated with a median
survival of 27 months. The high response rate of myeloma to
VAD (vincristine, doxorubicin and dexamethasone), a non-
alkylating agent-based regimen, was an exciting development
for patients with relapsed and refractory myeloma (Barlogie
et al., 1984). We reported the early results of a modified
VAD regimen given to newly diagnosed, relapsed and refrac-
tory patients in 1987. The response rate was 80% for pre-
viously untreated patients and 50% for relapsed or refractory
patients (Anderson et al.. 1987). From 1984 the VAD regi-
men has become our standard remission induction therapy
for multiple myeloma.
The aim of this paper is to report the results of the
treatment of multiple myeloma using VAD as remission
induction therapy in this institution.
Materials and meds
All patients with multiple myeloma referred to our unit were
treated with VAD unless serious concurrent medical condi-
tions precluded the use of high-dose dexamethasone (uncon-
trolled cardiac failure, unstable diabetes or chronic chest
infection, e.g. bronchiectasis).
The staging tests for myeloma included a modified skeletal
survey and bone marrow examination. Serum was taken for
protein and immunoelectrophoresis and quantification of
immunoglobulins. A 24 h urine specimen was collected for
quantification of light chains, total protein excretion and
creatinine clearance. In all cases the pathology was reviewed.
Myeloma was staged according to the Durie and Salmon
(1975) classification.
Two groups of patients entered the study: those with un-
treated multiple myeloma and those with relapsed or refrac-
tory disease. Relapsed myeloma was defined as progressive
disease with an increase (>25%) in urine light chains or
plasma immunoglobulins while the patient received the
therapy that produced the previous response. or in patients
who had discontinued therapy after achieving a response.
Refractory myeloma was defined as a >25% increase in
M-band protein despite therapy or failure of clinical im-
provement with no significant change in M band on chemo-
therapy.
Therapy
Patients received a continuous infusion of vincristine 1.6 mg
(total dose) with doxorubicin 36 mg m- over 4 days via a
central venous line or Portacath together with oral dexa-
methasone 40 mg daily for 4 days. VAD was repeated every
21 days. Initially 19 (13%) patients also received dexa-
methasone 40 mg daily for 4 days starting on the subsequent
eighth and 16th days of the first, third and fifth courses of
therapy.
With the first VAD patients were given allopurinol 300 mg
daily for 2 weeks. Prophylaxis was routinely given against
infection: cotrimoxazole 480 mg twice daily, increased to
960 mg twice daily after our first analysis had shown that
61% patients developed an infection (Anderson et al.. 1987).
and ketoconazole 400 mg daily. Cimetidine 400 mg twice
daily was used as prophylaxis for steroid-induced dyspepsia.
All agents were given for 7 days every time patients com-
menced dexamethasone. In addition. patients with renal
failure had an alkaline diuresis with the first course of VAD,
together with dialysis if appropriate.
The assessment of response after six courses of VAD was
according to the Chronic Leukaemia-Myeloma Task Force
(1973), except that the definition of complete response was
that described by Gore et al. (1989). The assessment of
toxicity was according to standard criteria (Miller et al.,
1981).
Results
From July 1984 to May 1992. 142 patients received VAD as
remission induction therapy for myeloma. The patients' char-
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1994acteristics are shown in Table I. Seventy-five patients were
previously untreated and 67 had either relapsed (31) or re-
fractory disease (36). Of the relapsed patients, 29 had
received prior alkylating agents and two had received doxo-
rubicin. Of the refractory patients. 30 had received prior
alkylating agents and six doxorubicin.
The median duration of follow-up (from first VAD to
death, or to median date last seen in the surviving patients) is
37 months for untreated patients and 51 months for
previously treated patients. The database was last updated in
June 1993.
Response
Response to therapy is summarised in Table II. The median
time to response was 6 weeks (range 5 days to 5 months). i.e.
a median of two courses. Of the previously untreated
patients. 20 (27%) achieved a complete response (CR) and 43
(57%) a partial response (PR). Of the previously treated
patients. two (3%) achieved a CR and 39 (58%) a PR. The
difference in CR rate between the two patient groups was
statistically significant (Chi-square P = 0.0003). Seventeen of
31 (55%) patients with relapsed disease and 24/36 (66%)
with refractory disease responded to VAD (chi-square
P = 0.46).
Subsequent therapy
Previously untreated patients who did not have progressive
myeloma after completion of VAD received melphalan 10 mg
day-' for five days and prednisolone 50 mg day-' for 5 days
every 6 weeks for a year. Previously treated patients were
given 3 million units of alpha interferon thrice weekly for 1
year. In addition. 23 patients have undergone a bone marrow
(BMT) or peripheral blood stem cell transplant (PBSCT).
Bone marrow andperipheral blood stem cell transplant
Since June 1986. 23 patients have received a transplant: eight
allografts from matched sibling donors (four CR, three PR,
one relapse), eight autografts (three CR, two PR. two stable
plateau. one in relapse), and seven peripheral stem cell trans-
plants following mobilisation with cyclophosphamide and
granulocyte colony-stimulating factor (G-CSF) three CR.
Table I Patient charactenstics
Relapsed and
lUntreated refractors
Number 75 67
Male 44 (59%) 42 (63%)
Female 31 (41%) 25 (37%)
Median age (range) 57 (25-80) 59 (38-75)
Stage 7 (9%) 0
IA 19 (25%) 12 (18%)
IIA 1 (1.3%) 1 (1.5%)
IIB 25 (33%) 42 (63%)
IIIA 23 (31%) 12 (18%)
IIIB
No courses median (range) 6 (1-9) 6 (1-15)
Median follow-up (months) from 37 51
VAD
Table II Response to therapy
Relapsed or
L'ntreated (75} refractory (67)
Complete response 20 (27%) 2 (3%)
Partial response 43 (57%) 39 (58%)
Stable 7 (9%) 15 (22%)
Progressed 1 (1%) 4 (6%)
Died 4 (5%) 7 (10%)
Median survival (months) 36 10
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three PR. one stable plateau). The age ranges (years) were
35-48 for allogeneic. 25-49 for autologous and 37-59 for
stem cell transplantation. All patients received 110mgm--
melphalan and total body irradiation (1200cGy in six frac-
tions over 3 days) before bone marrow or stem cell infusion.
PBSCT recipients also received alpha interferon maintenance
therapy following reconstitution.
Survival
The median survival from starting VAD is 36 months for
previously untreated patients and 10 months for the relapsed/
refractory patients (Figure 1). For previously untreated
patients the 75% survival was 14 months, and the 25%
survival has not been reached. The median survival from
diagnosis is 38 months for previously untreated patients and
39 months for patients with relapsed or refractory disease.
Analysis of survival by response after completion of VAD
(with patients censored at the time of BMT), in previously
untreated patients, has shown that the definition of CR used
may be of prognostic importance as survival was longer in
CR (not reached) than in PR patients (28 months; P = 0.03)
(Figure 2).
The median duration of follow-up for those patients who
received a transplant is 22 months from the date of first
VAD. The median survival has not yet been reached for this
subgroup of patients (Figure 3).
Transplantation as consolidation therapy
Of the 23 patients who had a transplant, eight have died.
Two allograft recipients died of graft-versus-host disease at 1
month post transplant, and two died of infection at 2.5 and
3.5 months: one from fungal infection and one from com-
bined cytomegalovirus infection and herpes simplex pneu-
> -
cL
Years from VAD
75 58 35 24 11 3
67 34 23 15 9 2 atrisk
Fgre 1 Survival for previously untreated patients and for those
with relapsed refractory disease.
100-
80
>
co 60
c CD
40
20-
.-I
I~~~~~~~I-
I_, .-I
;__,
CR (n=20)
-PR (n= 43)
--- SD (n= 7)
2 3
Years from VAD
4 5
Figre 2 Survival after VAD for patients according to res-
ponse.
u .V9 chm H rderson et a
0
0
0 cJ
0
100l
80
60
40
20
0
0 1 2 3
Years from transplant
23 14 6 5
Table m Symptomatic toxicity
Symptom No. (%)
Alopecia 119 (84)
Antibiotics for infection 76 (54)
Dyspepsia 52 (37)
Constipation 42 (30)
Paraesthesiae 40 (28)
Oedema 38 (27)
Line problems 34 (24)
Nausea and vomiting 30 (21)
Central nervous system 19 (13)
Candida infection 18 (13)
Heart failure 7 (5) i 5
3 1 atrisk
Flgwe 3 Survival after a bone marrow or stem cell trans-
plant.
monia. Four autograft patients died of progressive disease at
3.5-15.5 months post transplant. None of the seven patients
who received PBSCT have died (6-14 months post trans-
plant).
The median time for haematologial reconstitution of neu-
trophils to 0.5 x 109I-1 was 19 days for aIIoBMT, 17 days
for auto-BMT and 16 days for PBSCT patients. The median
time to platelets >20 x 191-' was 21 days for allo-BMT, 23
days for auto-BMT and 13 days for PBSCT patients.
Toxicity of VAD
Nine (6%) patients died within 30 days of the first VAD
treatment. Their median age was 64 years (range 38-75
years). Five died of myeloma (8-24 days after VAD), three
ofinfection and myeloma (4-30 days post VAD) and one of
progressive multifocal leucoencephalopathy. A further
patient discontinued chemotherapy after the first course and
died of a cerebral infarction on day 51, and another died of
pulmonary haemorrhage after the third course of VAD (day
62).
Symptomatic toxicity
This is summarised in Table III. Seventy-six patients (54%)
received antibiotics during VAD therapy: 31 (22%) needed
oral antibiotics, 31 (22%) intravenous antibiotics and 14
(10%) received both intravenous and oral antibiotics. Chest
infections were common, occurring in 40 (28%) patients.
Documented bacteraemia occurred in 22 (14%) patients.
Fifteen patients had Gram-positive isolates and seven (3%)
Gram-negative isolates. Two patients died following bacter-
aemia, one of Escherichia colt bacteraemia on day 4 and the
other of Streptococcus pnewnoniae pneumonia and bacter-
aemia on the 31st day after VAD.
Despite ketoconazole prophylxis, 18 (13X%) patients
developed oral candidiasis. Herpes zoster developed in five
(4%) patients during VAD therapy.
Nausea and vomiting was mild - 30 (21%) patients report-
ed vomiting (maximum WHO grade 2). Fifty-two (37%)
patients developed dyspepsia. These patients were given con-
tinuous cimetidine prophylaxis. Constipation occurred in 42
(30%).
Steroid-associated oedema was seen in 38 (27%) patients,
but did not necessitate a change of therapy. In seven patients
(5%) mild heart failure was documented and treated with
diuretics.
Problems with venous access occurred in 34 (24%) of 142
patients. The line fell out in 13 (9%), was replad because of
blockage in nine (6%), became infected and was removed in
two (1%), became infected and was salvaged with antibiotics
in three (2%) and in one (<1%) the Portacath insertion site
became infected and required antibiotics. One line insertion
was associated with a pneumothorax, and two (1%) patients
developed a venous thrombosis (axillary and subclavian
vein). In three patients with low platelet counts there was
local bruising at the line insertion site.
VAD is an out-patient regimen with acceptable toxicity.
Eighty-four per cent of previously untreated and 61% of
patients with relapsed/refractory myeloma responded to
VAD. There was a significant difference in CR rate: 27% in
previously untreated patients compared with 3% in patients
with relapsed/refractory disease (P = 0.0003). The median
time to response was 6 weeks, i.e. after two courses of VAD.
The median survival was 36 months for untreated patients
and 10 months for those with relapsed/refractory disease. For
the untreated patients (with censoring at the time of BMT)
survival is longer in patients who achieved a CR with VAD.
Increased survival has been described after CR by other
authors (Gore et al., 1989; Samson et al., 1989; Attal et al.,
1992). The importance of CR is currently being investigated
in a number of randomised trials. High-dose therapy may
improve the CR rate.
Selby et al. (1987) used high-dose melphalan (140 mgm-)
to achieve a response rate of 78% (27%CR) and a median
survival of 40 months in 41 previously untreated myeloma
patients. However, toxicity was marked with 17% mortaity
in the first 2 months. In a MRC trial ofcombination therapy
with ABCM (adriamycin, BCNU, cyclophosphamide and
melphalan) vs melphalan alone, the response rates were
similar [61% and 59% (8% CR)J, however median survival
was longer in the combination therapy arm: 32 vs 24 months
(MacLennan et al., 1992). Although comparing different
paient populations, our previously untreated patients who
received VAD then melphalan and prednisolone have a
similar outcome to those reported by the above authors.
BMT and PBSCT are ways of increasng treatment inten-
sity. We have found PBSCT to be well tolerated in patients
up to 60 years old. PBSCT has a lower procedure-related
mortality and morbidity in our hands than autologous or
allogeneic BMT. These observations have been confirmed at
our institution in 54 patients who have received PBSCT for
leukaemia or lymphoma. There was a shorter duration of
neutropenia, thrombocytopenia and hospitalisation than for
historical controls receiving autologous BMT (Pettengell et
al., 1993).
The role of combination therapy in myeloma may be
questioned after the meta-analysis of Gregory et al. (1992)
showed melphalan and prednisolone to be superior for
patients with a good prognosis and inferior for patients with
a poor prognosis. This overview included 18 trials, of which
12 had been started in the 1970s. Caution should be exercised
in extrapolating these results to modern chemotherapy with
improved supportive care.
Patients with relapsed/refractory disease had a higher res-
ponse rate to VAD than that reported by Alexanian et al.
(1986). Our patients generally had not received prior anthra-
cyclines, and this may explain the differences. Our
modification of VAD (omitting the steroids on days 9-12
and 17-20, and repeating courses every 21 days) has pro-
,
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duced similar results to those initially described by Barlogie
et al. (1984). However, some modifications of VAD may be
detrimental: the NCI (Canada) gave a modified VAD
regimen to patients with replapsed and refractory disease.
Therapy was effectively reduced with a 2 h infusion VAD
every 28 days. The observed response rate was only 27%
with a median survival of 7.6 months (Browman et al.,
1992).
Methods to improve response in patients with relapsed,
refractory disease are needed. High-dose therapy may not be
the answer: high-dose melphalan produced a 66% response
rate in patients with refractory disease, but the median sur-
vival was 10 months (Selby et al., 1987). High-dose therapy
with PBSCT produced a response in 4 of 11 patients with
VAD-resistant myeloma (Ventura et al., 1990). Allogeneic
BMT may be an option for patients up to 55 years old - 49
patients with non-responsive or progressive myeloma treated
with allo-BMT by the European Group for Bone Marrow
Transplantation have a projected long-term survival of
30-40% (Gahrton et al., 1991).
Interferon has shown activity in multiple myeloma. Ran-
domised trials have been conducted using interferon after
patients have responded to chemotherapy in myeloma. Some
have shown an advantage for maintenance interferon (Ma-
ndelli et al., 1990; Westin et al., 1991; Cunningham et al.,
1993), however, others have not (Ludwig et al., 1991). Ran-
domised tnrals of interferon in combination with chem-
otherapy have shown higher response rates in the interferon
group (Bjorkholm et al. 1991; Ludwig et al., 1991). Large,
national studies are under way to address the optimal use of
interferon.
New strategies are needed for improving the treatment of
relapsed/refractory myeloma. Options include the use of
maintenance interferon and dexamethasone (San Miguel et
al., 1990; Palumbo et al., 1992), anti-interleukin 6 mono-
clonal antibodies (Klein et al., 1990), or the use of agents to
reduce resistance to chemotherapy (Jonsson et al., 1992).
CR in multiple myeloma may be as important a prognostic
factor for long-term survival as in other haematological
malignancies. The high response rate of untreated myeloma
to VAD encourages its continued use for remission induction
therapy. Our present strategy in all VAD responders under
70 years of age is to consolidate with high-dose cyclophos-
phamide, harvest peripheral blood stem cells and proceed to
melphalan and total body irradiation with PBSCI and
maintenance imterferon.
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